AGNISTABIO
LIVE

Serial Number

98525680

Owner

AgnistaBio Inc.

Attorney

Enshan Hong

Filing Date

Apr 29, 2024

Add to watchlist:

No watchlists yet
View on USPTO

AGNISTABIO Trademark

Serial Number: 98525680

AGNISTABIO is a trademark filed by AgnistaBio Inc. on April 29, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently pending registration.

Owner Contact Info

AgnistaBio Inc.

530 Lytton Ave, Second Floor
Palo Alto, CA 94301

Entity Type: 03

Trademark Details

Filing Date

April 29, 2024

Registration Date

Not Registered

Published for Opposition

December 17, 2024

Goods & Services

Licensing of intellectual property; Licensing of intellectual property in the field of pharmaceuticals; Licensing of intellectual property in the field of medical and scientific technologies; legal services

Providing medical information in the field of inflammatory disease, immune related diseases, disorders and conditions prevention, screening, diagnosis and treatment; providing medical information in the field of cancer, tumor, malignancies, and related diseases, disorders, and conditions prevention, screening, diagnosis and treatment; providing medical information in the field of eye diseases, cardiovascular diseases, and brain disorder prevention, screening, diagnosis and treatment

Medical and scientific research in the field of inflammatory diseases, immune related diseases, disorders, and conditions treatment and diagnosis; medical and scientific research in the field of cancer, tumors, malignancies, and related diseases, disorders and conditions treatment and diagnosis; Medical and scientific research in the field of eye diseases, cardiovascular diseases and brain disorders treatment and diagnosis; Clinical research in the field of inflammatory diseases, immune related diseases, disorders, and conditions; Clinical research in the field of cancer, tumors, malignancies, and related diseases, disorders and conditions; Clinical research in the field of eye diseases, cardiovascular diseases and brain disorders, and conditions; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Scientific research and development; Conducting early evaluations in the field of new pharmaceuticals; Research and development of pharmaceutical and biopharmaceutical preparations and medicines; Pharmaceutical and biotechnology products development; Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical and biopharmaceutical research services in the fields of inflammatory diseases, immune related diseases, disorders, and conditions, cancer, tumors, malignancies, and related diseases, disorders, conditions, eye diseases, cardiovascular diseases, and brain disorders; Pharmaceutical and biopharmaceutical research services in the nature of biomarker identification; Pharmaceutical and biopharmaceutical research services, namely, artificial intelligence assisted drug discovery and development services; Software as a service services featuring artificial intelligence software for drug discovery and development; Scientific and technological services and research and design relating thereto in the nature of pharmaceutical research and development; Industrial analysis and research services in the nature of pharmaceutical research and development; Design and development of computer hardware and software

Pharmaceutical preparations for the treatment of inflammatory diseases, immune related diseases, disorders and conditions; biological preparations for the treatment of inflammatory diseases, immune related diseases, disorders and conditions; pharmaceutical preparations for the treatment of cancer, tumor, malignancies, and related diseases, disorders, and conditions; biological preparations for the treatment of cancer, tumor, malignancies, and related diseases, disorders, and conditions; pharmaceutical preparations for the treatment of eye diseases; biological preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; biological preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of brain disorders; biological preparations for the treatment of brain disorders

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 28, 2026 EXRA
SOU EXTENSION 3 GRANTED
Apr 27, 2026 EX3G
SOU EXTENSION 3 FILED
Apr 27, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 27, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 12, 2025 EXRA
SOU EXTENSION 2 GRANTED
Nov 11, 2025 EX2G
SOU EXTENSION 2 FILED
Nov 11, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 11, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 3, 2025 EXRA
SOU EXTENSION 1 GRANTED
Apr 3, 2025 EX1G
SOU EXTENSION 1 FILED
Apr 2, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 2, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 17, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 17, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 11, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 21, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 21, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 21, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 21, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 21, 2024 CNEA
ASSIGNED TO EXAMINER
Nov 14, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 23, 2024 NWOS
NEW APPLICATION ENTERED
Apr 29, 2024 NWAP